Skip to main content
. Author manuscript; available in PMC: 2014 Oct 22.
Published in final edited form as: ACS Nano. 2013 Sep 26;7(10):8605–8615. doi: 10.1021/nn403311c

Figure 2.

Figure 2

(a–d) 40 minute uptake of p5RHH/Alexa488-siRNA nanoparticles shows that 60% of the treated cells take up (a) p5RHH/siRNA nanoparticles. The presence of endocytosis inhibitors indicates that (b) 100μg/mL filipin (caveolae inhibitor) and (c) 10μM PAO (clathrin mediated endocytosis inhibitor) do not inhibit p5RHH/siRNA nanoparticle uptake. Alternatively, treatment with (d) macropinocytosis inhibitor (EIPA, 80μM) nearly abolishes nanoparticle uptake. (e–j) Colocalization as determined by confocal microscopy shows that p5RHH/Cy-3 siRNA nanoparticles are taken up with FITC-70kDa dextran (j) but not FITC-transferrin (i). Scale bar 10μm.